Document:

REGISTRATION RIGHTS AGREEMENT

 Exhibit 10.7 
  
 EXHIBIT “C” 
  
 Registration Rights 
  
 1. Definitions. 
  
 (a) As used in this Exhibit C, the following terms shall have the meanings: 
  
 1. “Affiliate,” of any specified Person means any other Person who directly, or indirectly through one or
more intermediaries, is in control of, is controlled by, or is under common control with, such specified Person. For purposes of this definition, control of a Person means the power, directly or indirectly, to direct or cause the direction of the
management and policies of such Person whether by contract, securities ownership or otherwise; and the terms “controlling” and “controlled” have the respective meanings correlative to the foregoing. 
  
 2. “Commission” means the Securities and Exchange
Commission. 
  
 3. “Company” shall mean Paradigm
Genetics, Inc. 
  
 4. “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder, or any similar successor statute. 
  
 5. “Holder” means Stonegate Securities, Inc. and any permitted transferee or assignee of Registrable Securities who agrees to become
bound by all of the terms and provisions of this Exhibit C. 
  
 6.
“Person” means any individual, partnership, corporation, limited liability company, joint stock company, association, trust, unincorporated organization, or a government agency or political subdivision thereof. 
  
 7. “Placement” means any offering of securities of the
Company pursuant to which Holder serves as a placement agent or underwriter, whether on a best efforts basis or otherwise. 
  
 8. “Prospectus” means the prospectus (including any preliminary prospectus and/or any final prospectus filed pursuant to Rule 424(b)
under the Securities Act and any prospectus that discloses information previously omitted from a prospectus filed as part of an effective registration statement in reliance on Rule 430A under the Securities Act) included in the Registration
Statement, as amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement and by all other amendments and supplements to such
prospectus, including all material incorporated by reference in such prospectus and all documents filed after the date of such prospectus by the Company under the Exchange Act and incorporated by reference therein. 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 9. “Public Offering” means an offer registered with the Commission and the appropriate
state securities commissions by the Company of its Common Stock and made pursuant to the Securities Act. 
  
 10. “Registrable Securities” means the shares of common stock issued to Stonegate Securities, Inc. or its designated affiliates pursuant
to the terms of the Placement Agency Agreement; provided, however, a share of common stock shall cease to be a Registrable Security for purposes of this Exhibit C when it no longer is a Restricted Security. 
  
 11. “Registration Statement” means a registration statement
of the Company filed on Form S-3 under the Securities Act providing for the registration of, and the sale on a continuous or delayed basis by the holders of, all of the Registrable Securities pursuant to Rule 415 under the Securities Act, including
the Prospectus contained therein and forming a part thereof, any amendments to such registration statement and supplements to such Prospectus, and all exhibits and other material incorporated by reference in such registration statement and
Prospectus. In the event that Form S-3 is unavailable for such a registration, the Company shall use such other form as is available for such a registration. 
  
 12. “Restricted Security” means any share of common stock except any that (i) have been registered pursuant to an effective registration
statement under the Securities Act and sold in a manner contemplated by the prospectus included in such registration statement, (ii) have been transferred in compliance with the resale provisions of Rule 144 under the Securities Act (or any
successor provision thereto) or is transferable pursuant to paragraph (k) of Rule 144 under the Securities Act (or any successor provision thereto), or (iii) otherwise has been transferred and are not subject to transfer restrictions under the
Securities Act. 
  
 13. “Securities Act” means
the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder, or any similar successor statute. 
  

	 	(a)	All capitalized terms used and not defined herein have the respective meaning assigned to them in the Subscription Agreement. 

  
 2. Registration. 
  

	 	(a)	Initial Registration Statement. The Company hereby grants to Holder, with respect to the Registrable Securities, registration rights identical to those granted to the
purchasers in the Placement and will include the Registrable Securities in any registration statement filed for the purchasers in the Placement. 

  

	 	(b)	Piggyback Registration Rights. 

  
 (i) Whenever the Company proposes to register any of its Common Shares or any other common shares of the Company under the Securities Act (other than a
(A) on Form S-8 or S-4 or any successor or similar forms, (B) relating to Common Shares or any other common shares of the Company issuable upon exercise of employee or consultant share options or in 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 connection with any employee benefit or similar plan of the Company or (C) in connection with a direct or indirect
acquisition by the Company of another Person or any transaction with respect to which Rule 145 (or any successor provision) under the Securities Act applies), whether or not for sale for its own account, it will each such time, give prompt written
notice at least 20 days prior to the anticipated filing date of the registration statement relating to such registration to the Holders, which notice shall set forth such Holders’ rights under this Section 2(b) and shall offer the Holders the
opportunity to include in such registration statement such number of Registrable Securities as the Holders may request. Upon the written request of a Holder made within 10 days after the receipt of notice from the Company (which request shall
specify the number of Registrable Securities intended to be disposed of by such Holders), the Company will use its best efforts to effect the registration under the Securities Act of all Registrable Securities that the Company has been so requested
to register by the Holders, to the extent requisite to permit the disposition of the Registrable Securities to be so registered; provided, however, that (A) if such registration involves a Public Offering, the Holders must sell their Registrable
Securities to the underwriters on the same terms and conditions as apply to the Company and (B) if, at any time after giving written notice of its intention to register any Registrable Securities pursuant to this Section 2(b) and prior to the
effective date of the registration statement filed in connection with such registration, the Company shall determine for any reason not to register such Registrable Securities, the Company shall give written notice to the Holders and, thereupon,
shall be relieved of its obligation to register any Registrable Securities in connection with such registration. The Company’s obligations under this Section 2(b) shall terminate on the date that the registration statement to be filed in
accordance with Section 2(a) is declared effective by the Commission. 
  
 (ii) If a registration pursuant to this Section 2(b) involves a Public Offering and the managing underwriter thereof advises the Company that, in its view, the number of Common Shares, if any, or other Common Shares that the Company and the
Holders intend to include in such registration exceeds the largest number of Common Shares (including any other Common Shares or warrants of the Company) that can be sold without having an adverse effect on such Public Offering (the “Maximum
Offering Size”), the Company will include in such registration only that number of Common Shares which does not exceed the Maximum Offering Size, in the following order of priorities: (1) first, all securities the Company proposes to sell
for its own account, (2) second, up to the full number of securities proposed to be registered for the account of the holders of securities entitled to inclusion of their securities in the Registration Statement by reason of demand registration
rights, and (3) third, the securities requested to be registered by other holders of securities entitled to participate in the registration, drawn from them pro-rata based on the number of shares each has requested to be included in such
registration and the Holders pursuant to this Exhibit C. 
  
 If as a result of the
proration provisions of this Section 2(b)(ii), the Holders are not entitled to include all such Registrable Securities in such registration, such Holders may elect to withdraw their request to include any Registrable Securities in such registration.
Notwithstanding the foregoing, the Company shall have no obligations under this Section 2(b) hereof at any time that such Registrable Securities are the subject of an effective registration statement. 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 3. Obligations of the Company. In connection with the registration of the Registrable Securities, the
Company shall use its reasonable best efforts to: 
  

	 	(a)	Subject to the provisions of Section 3(o) hereof, promptly (i) prepare and file with the Commission such amendments (including post-effective amendments) to the Registration
Statement and supplements to the Prospectus as may be necessary to keep the Registration Statement continuously effective and in compliance with the provisions of the Securities Act applicable thereto so as to permit the Prospectus forming part
thereof to be current and useable by Holders for resales of the Registrable Securities for a period of two years from the date the Registration Statement is first declared effective by the Commission (the “Effective Time”) or such shorter
period that will terminate when all the Registrable Securities covered by the Registration Statement have been sold pursuant thereto in accordance with the plan of distribution provided in the Prospectus, transferred pursuant to Rule 144 under the
Securities Act or otherwise transferred in a manner that results in the delivery of new securities not subject to transfer restrictions under the Securities Act (the “Registration Period”) and (ii) take all lawful action such that each of
(A) the Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein,
not misleading and (B) the Prospectus forming part of the Registration Statement, and any amendment or supplement thereto, does not at any time during the Registration Period include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, the Company’s obligations hereunder shall terminate as to
any Holder at such time as that Holder’s Registrable Securities can be sold under Rule 144(k); 

  

	 	(b)	During the Registration Period, comply with the provisions of the Securities Act with respect to the Registrable Securities of the Company covered by the Registration Statement
until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the Holders as set forth in the Prospectus forming part of the Registration Statement; 

  

	 	(c)	(i) Prior to the filing with the Commission of any Registration Statement (including any amendments thereto) and the distribution or delivery of any Prospectus (including any
supplements thereto), provide draft copies thereof (including a copy of the accountant’s consent letter to be included in the filing) to Stonegate Securities, Inc. (“Stonegate”) and reflect in such documents all such comments as
Stonegate reasonably may propose; and (ii) furnish to each Holder whose Registrable Securities are included in the Registration Statement, (A) promptly after the same is prepared and publicly distributed, filed with the Commission, or received by
the Company, one copy of the Registration Statement, each Prospectus, and each amendment or supplement thereto, and (B) such number of copies of the Prospectus and all amendments and supplements thereto and such other documents, as such Holder may
reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holder; 

  

 Placement Agency Agreement paradigm genetics Final Execution 

	 	(d)	(i) Register or qualify the Registrable Securities covered by the Registration Statement under such securities or “Blue Sky” laws of all jurisdictions requiring Blue Sky
registration or qualification, (ii) prepare and file in such jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof at
all times during the Registration Period, (iii) take all such other lawful actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all such other lawful
actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (A) qualify to do business
in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (B) subject itself to general taxation in any such jurisdiction or (C) file a general consent to service of process in any such jurisdiction;

  

	 	(e)	As promptly as practicable after becoming aware of such event, notify each Holder of the occurrence of any event, as a result of which the Prospectus included in the Registration
Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, and promptly prepare an amendment to the Registration Statement and supplement to the Prospectus to correct such untrue statement or omission, and deliver a number of copies of such supplement and amendment to each Holder as such Holder
may reasonably request; 

  

	 	(f)	Notify each Holder who holds Registrable Securities being sold (or, in the event of an underwritten offering, the managing underwriters) of the issuance by the Commission of any
stop order or other suspension of the effectiveness of the Registration Statement on the date of receipt of any such stop order or other suspension, and take all lawful action to effect the withdrawal, recession or removal of such stop order or
other suspension; 

  

	 	(g)	Cause all the Registrable Securities covered by the Registration Statement to be listed not later than the date that the Registration Statement is declared effective by the
Commission on the principal national securities exchange, or included in an inter-dealer quotation system of a registered national securities association, on or in which securities of the same class or series issued by the Company are then listed or
included; 

  

 Placement Agency Agreement paradigm genetics Final Execution 

	 	(h)	Maintain a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the Registration Statement;

  

	 	(i)	Cooperate with the Holders who hold Registrable Securities being offered to facilitate the timely preparation and delivery of certificates for the Registrable Securities to be
offered pursuant to the registration statement and enable such certificates for the Registrable Securities to be in such denominations or amounts, as the case may be, as the Holders reasonably may request and registered in such names as the Holder
may request; and, within three business days after a registration statement which includes Registrable Securities is declared effective by the Commission, deliver and cause legal counsel selected by the Company to deliver to the transfer agent for
the Registrable Securities (with copies to the Holders whose Registrable Securities are included in such registration statement) an appropriate instruction and, to the extent necessary, an opinion of such counsel; 

  

	 	(j)	Take all such other lawful actions reasonably necessary to expedite and facilitate the disposition by the Holders of their Registrable Securities in accordance with the intended
methods therefor provided in the Prospectus which are customary under the circumstances; 

  

	 	(k)	Make generally available to its security holders as soon as practicable, but in any event not later than three (3) months after (i) the effective date (as defined in Rule 158(c)
under the Securities Act) of the Registration Statement, and (ii) the effective date of each post-effective amendment to the Registration Statement, as the case may be, an earnings statement of the Company and its subsidiaries complying with Section
11(a) of the Securities Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158) and which delivery shall be deemed complied with by the Company’s filing of its reports under the
Exchange Act; 

  

	 	(l)	In the event of an underwritten offering, promptly include or incorporate in a Prospectus supplement or post-effective amendment to the Registration Statement such information as
the managers reasonably agree should be included therein and to which the Company does not reasonably object and make all required filings of such Prospectus supplement or post-effective amendment as soon as practicable after it is notified of the
matters to be included or incorporated in such Prospectus supplement or post-effective amendment; 

  

	 	(m)	In connection with any underwritten offering, make such representations and warranties to the Holders participating in such underwritten offering and to the managers, in form,
substance and scope as are customarily made by the Company to underwriters in secondary underwritten offerings; 

  

 Placement Agency Agreement paradigm genetics Final Execution 

	 	(n)	In connection with any underwritten offering, deliver such documents and certificates as may be reasonably required by the managers, if any; and 

  

	 	(o)	Notwithstanding anything to the contrary in Section 3, at any time after the Registration Statement has been declared effective, the Company may delay the disclosure of material
non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company and its counsel, in the best interest of the Company (a “Grace Period”); provided, that the Company shall
promptly (i) notify the Holders in writing of the existence of material non-public information giving rise to a Grace Period and the date on which the Grace Period will begin, and (ii) notify the Holders in writing in advance of, or on the same date
on which, the Grace Period ends; and, provided further, that during any consecutive 365 day period, there shall be only two Grace Periods, such Grace Periods in total not to exceed 45 days. For purposes of determining the length of a Grace Period
above, the Grace Period shall begin on and include the date the Holders receive the notice referred to in clause (i) and shall end on and include the date specified as the Grace Period ending date in the notice referred to in clause (ii).

  
 Notwithstanding the foregoing, the Company shall have no
obligations under Section 3(l) through (n) unless it is effecting an underwritten offering pursuant to Section 2(b). 
  
 4. Obligations of the Holders. In connection with the registration of the Registrable Securities, the Holders shall have the following obligations, which
obligations shall be several and not joint: 
  

	 	(a)	Prior to the first anticipated filing date of the Registration Statement under Section 2 hereof, the Company shall provide the Holders with a draft of the Registration Statement,
including such information about the Holder as has been provided in the Questionnaire completed by the Holder, together with whatever confirmations, certificates or consents as may be reasonably requested by the Company. In connection with any other
Registration Statement including the Holders, it shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Exhibit C with respect to the Registrable Securities of a particular Holder that such
Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration
of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least ten business days prior to the first anticipated filing date of the Registration Statement, the
Company shall notify each Holder and its counsel, whether in-house or otherwise (“Counsel”) of the information the Company requires from each such Holder (the “Requested Information”) if such Holder elects to have any of its
Registrable Securities 

  

 Placement Agency Agreement paradigm genetics Final Execution 

 included in the Registration Statement. If at least four business days prior to the anticipated filing
date the Company has not received the Requested Information from a Holder (a “Non-Responsive Holder”) or its Counsel, then the Company shall send such Non-Responsive Holder and its Counsel a reminder of such information request. If at
least two business days prior to the anticipated filing date the Company still has not received the Requested Information from such Non-Responsive Holder or its Counsel, then the Company may file the Registration Statement without including
Registrable Securities of such Non-Responsive Holder. However, promptly upon receipt of the Requested Information, and at the expense of the Non-Responsive Holder, the Company shall file such amendment(s) to the Registration Statement as may be
necessary to include therein the Registrable Securities of the Non-Responsive Holder. 
  

	 	(b)	Each Holder by its acceptance of the Registrable Securities agrees to cooperate with the Company in connection with the preparation and filing of the Registration Statement
hereunder, unless such Holder has notified the Company in writing of its election to exclude all of its Registrable Securities from the Registration Statement; the Company shall, on its part, ensure that Item 507 of Regulation S-K of the Securities
Act (regarding information on the selling security holders) be complied with in connection with its preparation and filing of the Registration Statement hereunder; 

  

	 	(c)	As promptly as practicable after becoming aware of such event, notify the Company of the occurrence of any event, as a result of which the Prospectus included in the Registration
Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading; and 

  

	 	(d)	Each Holder agrees that, upon receipt of any notice from the Company of the occurrence of any event of the kind described in Section 3(e) or 3(f), it shall immediately discontinue
its disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Holder’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 3(e) and, if so
directed by the Company, such Holder shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in such Holder’s possession, of the Prospectus covering such
Registrable Securities current at the time of receipt of such notice. 

  

 Placement Agency Agreement paradigm genetics Final Execution 

 5. Expenses of Registration. All expenses, other than underwriting discounts and commissions, incurred in
connection with registrations, filings or qualifications pursuant to Section 3, but including, without limitation, all registration, listing, and qualifications fees, printing and engraving fees, accounting fees, and the fees and disbursements of
counsel for the Company shall be borne by the Company. Any expenses of registration of counsel for the Holders shall be borne by the holders of the Registrable Securities. 
  
 6. Indemnification and Contribution. 
  

	 	(a)	The Company shall indemnify and hold harmless each Holder and each underwriter, if any, which facilitates the disposition of Registrable Securities, and each of their respective
officers and directors and each person who controls such Holder or underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (a “Company Indemnified Person”) from and against any losses, claims,
damages or liabilities, joint or several, to which such Company Indemnified Person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are
based upon an untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the
statements therein, not misleading, or arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Prospectus or an omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and the Company hereby agrees to reimburse such Company Indemnified Person for all reasonable legal and other
expenses incurred by them in connection with investigating or defending any such action or claim as and when such expenses are incurred; provided, however, that the Company shall not be liable to any such Company Indemnified Person in any such case
to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue statement or alleged untrue statement made in, or an omission or alleged omission from, such Registration Statement or Prospectus in reliance
upon and in conformity with written information furnished to the Company by such Company Indemnified Person expressly for use therein or (ii) in the case of the occurrence of an event of the type specified in Section 3(e), the use by the Company
Indemnified Person of an outdated or defective Prospectus after the Company has provided to such Company Indemnified Person written notice that such Prospectus is outdated or defective. 

  

	 	(b)	Indemnification by the Holders. Each Holder agrees, as a consequence of the inclusion of any of its Registrable Securities in a Registration Statement, severally and not
jointly, to (i) indemnify and hold harmless the Company, its directors (including any person who, with his or her consent, is named in the Registration Statement as a director nominee of the Company), its officers and each person, if

  

 Placement Agency Agreement paradigm genetics Final Execution 

 any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act (“Holder Indemnified Person”), against any losses, claims, damages or liabilities to which the Holder Indemnified Person may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in such Registration Statement or Prospectus or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in light of the circumstances under which they were made, in the case of the Prospectus), not misleading, in each case to
the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made by such Holder in reliance upon and in conformity with written information furnished to the Company by such holder
expressly for use therein; provided, however, that no Holder shall be liable under this Section 6(b) for any amount in excess of the gross proceeds paid to such Holder in respect of shares sold by it, and (ii) reimburse the Holder Indemnified Person
for any legal or other expenses incurred in connection with investigating or defending any such action or claim as such expenses are incurred. 
  

	 	(c)	Notice of Claims, etc. Promptly after receipt by a party seeking indemnification pursuant to this Section 6 (an “Indemnified Party”) of written notice of any
investigation, claim, proceeding or other action in respect of which indemnification is being sought (each, a “Claim”), the Indemnified Party promptly shall notify the party against whom indemnification pursuant to this Section 6 is being
sought (the “Indemnifying Party”) of the commencement thereof; but the omission to so notify the Indemnifying Party shall not relieve it from any liability that it otherwise may have to the Indemnified Party, except to the extent that the
Indemnifying Party is materially prejudiced and forfeits substantive rights and defenses by reason of such failure. In connection with any Claim as to which both the Indemnifying Party and the Indemnified Party are parties, the Indemnifying Party
shall be entitled to assume the defense thereof. Notwithstanding the assumption of the defense of any Claim by the Indemnifying Party, the Indemnified Party shall have the right to employ separate legal counsel and to participate in the defense of
such Claim, and the Indemnifying Party shall bear the reasonable fees, out-of-pocket costs and expenses of such separate legal counsel to the Indemnified Party if (and only if): (x) the Indemnifying Party shall have agreed to pay such fees, costs
and expenses, (y) the Indemnified Party and the Indemnifying Party shall reasonably have concluded that representation of the Indemnified Party by the Indemnifying Party by the same legal counsel would not be appropriate due to actual or, as
reasonably determined by legal counsel to the Indemnified Party, potentially differing interests between such parties in the conduct of the defense of such Claim, or if there may be legal defenses available to the Indemnified Party that are in
addition to or disparate from those available to the Indemnifying Party, or (z) the Indemnifying Party shall have failed to employ 

  

 Placement Agency Agreement paradigm genetics Final Execution 

 legal counsel reasonably satisfactory to the Indemnified Party within a reasonable period of time after
notice of the commencement of such Claim. If the Indemnified Party employs separate legal counsel in circumstances other than as described in clauses (x), (y) or (z) above, the fees, costs and expenses of such legal counsel shall be borne
exclusively by the Indemnified Party. Except as provided above, the Indemnifying Party shall not, in connection with any Claim in the same jurisdiction, be liable for the fees and expenses of more than one firm of counsel for the Indemnified Party
(together with appropriate local counsel). The Indemnified Party shall not, without the prior written consent of the Indemnifying Party (which consent shall not unreasonably be withheld), settle or compromise any Claim or consent to the entry of any
judgment that does not include an unconditional release of the Indemnifying Party from all liabilities with respect to such Claim or judgment. 
  

	 	(d)	Contribution. If the indemnification provided for in this Section 6 is unavailable to or insufficient to hold harmless an Indemnified Person under subsection (a) or (b) above
in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims,
damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and the Indemnified Party in connection with the statements or omissions which resulted in such
losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such Indemnifying Party or by such Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6(d) were determined by pro
rata allocation (even if the Holders or any underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 6(d). The amount paid
or payable by an Indemnified Party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such Indemnified
Party in connection with investigating or defending any such action or claim. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The obligations of the Holders and any underwriters in this Section 6(d) to contribute shall be several in proportion to the percentage of Registrable Securities registered or underwritten, as the case
may be, by them and not joint. 

  

 Placement Agency Agreement paradigm genetics Final Execution 

	 	(e)	Notwithstanding any other provision of this Section 6, in no event shall any (i) Holder be required to undertake liability to any person under this Section 6 for any amounts in
excess of the dollar amount of the gross proceeds to be received by such Holder from the sale of such Holder’s Registrable Securities pursuant to any Registration Statement under which such Registrable Securities are to be registered under the
Securities Act. 

  

	 	(f)	The obligations of the Company under this Section 6 shall be in addition to any liability which the Company may otherwise have to any Indemnified Person and the obligations of any
Indemnified Person under this Section 6 shall be in addition to any liability which such Indemnified Person may otherwise have to the Company. The remedies provided in this Section 6 are not exclusive and shall not limit any rights or remedies which
may otherwise be available to an indemnified party at law or in equity. 

  
 7. Rule 144. With a view to making available to the Holders the benefits of Rule 144 under the Securities Act or any other similar rule or regulation of the Commission that may at any time permit the Holders to sell securities
of the Company to the public without registration (“Rule 144”), the Company agrees to: 
  

	 	(a)	comply with the provisions of paragraph (c) (1) of Rule 144; and 

  

	 	(b)	file with the Commission in a timely manner all reports and other documents required to be filed by the Company pursuant to Section 13 or 15(d) under the Exchange Act; and, if at
any time it is not required to file such reports but in the past had been required to or did file such reports, it will, upon the request of any Holder, make available other information as required by, and so long as necessary to permit sales of,
its Registrable Securities pursuant to Rule 144. 

  
 8.
Assignment. The rights to have the Company register Registrable Securities pursuant to this Exhibit C may be assigned or transferred only with the prior written consent of the Company, and any such assignment or transfer without such
consent shall be void and of no effect, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, such consent of the Company shall not be required with respect to any assignment or transfer of Registrable Securities to an
affiliate of Subscriber, including for this purpose if Subscriber is an investment company, any fund or account advised by Subscriber’s investment adviser or any affiliate thereof. In the event of any such permitted assignment or transfer by
the Holders to any permitted transferee of all or any portion of such Registrable Securities such transfer will be allowed only if: (a) the Holder agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement
is furnished to the Company within a reasonable time after such assignment, (b) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (i) the name and address of such transferee or assignee and
(ii) the securities with respect to which such registration rights are being transferred or assigned, (c) immediately following such transfer or assignment, the securities so transferred or assigned to the transferee or assignee constitute
Restricted Securities, and (d) at or before the time the Company received the written notice contemplated by clause (b) of this sentence the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained
herein. 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 9. Amendment and Waiver. Any provision of this Exhibit C may be amended and the observance thereof may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and Holders who hold a majority interest of the Registrable Securities. Any amendment or waiver effected in
accordance with this Section 9 shall be binding upon each Holder and the Company. 
  
 10. Miscellaneous. 
  

	 	(a)	A person or entity shall be deemed to be a holder of Registrable Securities whenever such person or entity owns of record such Registrable Securities. If the Company receives
conflicting instructions, notices or elections from two or more persons or entities with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such
Registrable Securities. 

  

	 	(b)	Except as may be otherwise provided herein, any notice or other communication or delivery required or permitted hereunder shall be in writing and shall be delivered personally or
sent by certified mail, postage prepaid, or by a nationally recognized overnight courier service as follows, and shall be deemed given when actually received. 

  

			
	if to the Company, to:	  	 Paradigm Genetics, Inc.
 108 Alexander Drive

Research Triangle Park,
 North Carolina
 Facsimile: (919) 425-2915
 Attn: J. Barry Buzogany, Esq.

		
	if to the Holders, to:	  	 Stonegate Securities, Inc.
 5940 Sherry Lane, Suite
410
 Dallas, Texas 75225
 Facsimile: (214) 987-1981
 Attn: Mr. Scott Griffith, President

  
 The Company or any Holder may change
the foregoing address by notice given pursuant to this Section 10(b). 
  

 Placement Agency Agreement paradigm genetics Final Execution 

	 	(c)	Failure of any party to exercise any right or remedy under this Exhibit C or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver
thereof. 

  

	 	(d)	This Exhibit C shall be governed by and interpreted in accordance with the laws of the State of Delaware. 

  

	 	(e)	The remedies provided in this Exhibit C are cumulative and not exclusive of any remedies provided by law. If any term, provision, covenant or restriction of this Exhibit C is held
by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired
or invalidated, and the parties hereto shall use their best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby
stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable. 

  

	 	(f)	The Company shall not enter into any agreement with respect to its securities that is inconsistent with the rights granted to the holders of Registrable Securities in this Exhibit C
or otherwise conflicts with the provisions hereof. The Company is not currently a party to any agreement granting any registration rights with respect to any of its securities to any person which conflicts with the Company’s obligations
hereunder or gives any other party the right to include any securities in any Registration Statement filed pursuant hereto, except for such rights and conflicts as have been irrevocably waived. 

  

	 	(g)	This Exhibit C, the Placement Agency Agreement, the Initial Warrants and the Representative’s Warrant constitute the entire agreement among the parties hereto with respect to
the subject matter hereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein. This Exhibit C and the Subscription Agreements supersede all prior agreements and undertakings among the
parties hereto with respect to the subject matter hereof. 

  

	 	(h)	Subject to the requirements of Section 8 hereof, this Exhibit C shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto.

  

	 	(i)	All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as the context may require. 

  

	 	(j)	The headings in this Exhibit C are for convenience of reference only and shall not limit or otherwise affect the meaning thereof. 

  

 Placement Agency Agreement paradigm genetics Final ExecutionFORM OF STONEGATE SECURITIES INC. WARRANT

 Exhibit 10.8 
  
 EXHIBIT A1 
  
 Form of Initial Warrant 
 (See
attached) 
  

 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS, HAVE BEEN TAKEN FOR INVESTMENT, AND MAY NOT BE SOLD OR TRANSFERRED OR OFFERED FOR SALE OR TRANSFER UNLESS A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES
LAWS WITH RESPECT TO SUCH SECURITIES IS THEN IN EFFECT, OR IN THE OPINION OF COUNSEL (WHICH OPINION IS REASONABLY SATISFACTORY TO THE ISSUER OF THESE SECURITIES), SUCH REGISTRATION UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS IS NOT
REQUIRED. 
  

			
	 Dated: July 14, 2004
	  	Warrant to Purchase
	 	  	 100,000 Shares

  
 PARADIGM GENETICS, INC.

  
 (Incorporated under the laws of the State of Delaware)

  
 WARRANT FOR THE PURCHASE OF SHARES OF COMMON STOCK

  
 Warrant Price: $0.72 per share, subject to adjustment as
provided below: 
  
 THIS IS TO CERTIFY that, for value
received, Stonegate Securities, Inc. and its registered assigns (collectively, the “Holder”), is entitled to purchase, subject to the terms and conditions hereinafter set forth, up to One Hundred Thousand (100,000) shares of the
common stock, no par value (“Common Stock”), of Paradigm Genetics, Inc., a Delaware corporation (the “Company”), and to receive certificate(s) for the Common Stock so purchased. 
  
 1. Exercise Period and Vesting. This Warrant shall vest and become
exercisable upon on or about two months from the date of the issuance of the Warrant if the Board of Directors of the Company determines such Warrant shall become exercisable in its sole discretion. The management of the Company will inform the
Holder of its recommendation to the Board regarding exercisability on or about such date, but no later than 30 days after such date. The exercise period is the period beginning on the date this Warrant vests and ending at 5:00 p.m., Dallas, Texas
time, on July 13, 2009 (the “Exercise Period”). This Warrant will terminate automatically and immediately upon the expiration of the Exercise Period. 
  
 2. Exercise of Warrant; Cashless Exercise. This Warrant may be exercised, in whole or in part, at any time and from
time to time during the Exercise Period. Such exercise shall be accomplished by tender to the Company of the purchase price set forth above as the warrant price per share multiplied by the number of shares being purchased (the “Warrant
Price”), either (a) in cash, by wire transfer or by certified check or bank cashier’s check, payable to the order of the Company, or (b) by surrendering such number of shares of Common Stock received upon exercise of this Warrant with
a current market price equal to the Warrant Price (a “Cashless Exercise”), together with presentation and surrender to the Company of this Warrant 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 with an executed subscription in substantially the form attached hereto as Exhibit A (the
“Subscription”). Upon receipt of the foregoing, the Company will deliver to the Holder, as promptly as possible, a certificate or certificates representing the shares of Common Stock so purchased, registered in the name of the
Holder or its transferee (as permitted under Section 3 below). With respect to any exercise of this Warrant, the Holder will for all purposes be deemed to have become the holder of record of the number of shares of Common Stock purchased hereunder
on the date this Warrant, a properly executed Subscription and payment of the Warrant Price is received by the Company (the “Exercise Date”), irrespective of the date of delivery of the certificate evidencing such shares, except
that, if the date of such receipt is a date on which the stock transfer books of the Company are closed, such person will be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock
transfer books are open. Fractional shares of Common Stock will not be issued upon the exercise of this Warrant. In lieu of any fractional shares that would have been issued but for the immediately preceding sentence, the Holder will be entitled to
receive cash equal to the current market price of such fraction of a share of Common Stock on the trading day immediately preceding the Exercise Date. In the event this Warrant is exercised in part, the Company shall issue a new Warrant to the
Holder covering the aggregate number of shares of Common Stock as to which this Warrant remains exercisable for. 
  
 If the Holder elects to conduct a Cashless Exercise, the Company shall cause to be delivered to the Holder a certificate or certificates representing the
number of shares of Common Stock computed using the following formula: 
  

					
	X	  	=	  	Y (A-B)
	 	  	 	  	      A

  

					
	Where:	 	 	  	 
	 	 	X	  	= the number of shares of Common Stock to be issued to Holder;
			
	 	 	Y	  	= the portion of the Warrant (in number of shares of Common Stock) being exercised by Holder (at the date of such calculation);
			
	 	 	A	  	= the fair market value of one share of Common Stock on the Exercise Date (as calculated below); and
			
	 	 	B	  	= Warrant Price (as adjusted to the date of such calculation).

  
 For purposes of the
foregoing calculation, “fair market value of one share of Common Stock on the Exercise Date” shall mean: (i) if the principal trading market for such securities is a national or regional securities exchange, the average closing
price on such exchange for the ten (10) trading days immediately prior to such Exercise Date; (ii) if sales prices for shares of Common Stock are reported by the Nasdaq National Market System or Nasdaq Small Cap Market (or a similar system then in
use), the average last reported sales price for the ten (10) trading days immediately prior to such Exercise Date; or (iii) if neither (i) nor (ii) above are 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 applicable, and if bid and ask prices for shares of Common Stock are reported in the over-the-counter market by Nasdaq
(or, if not so reported, by the National Quotation Bureau), the average of the high bid and low ask prices so reported for the ten (10) trading days immediately prior to such Exercise Date. Notwithstanding the foregoing, if there is no reported
closing price, last reported sales price, or bid and ask prices, as the case may be, for the period in question, then the current market price shall be determined as of the latest ten (10) day period prior to such day for which such closing price,
last reported sales price, or bid and ask prices, as the case may be, are available, unless such securities have not been traded on an exchange or in the over-the-counter market for 30 or more days immediately prior to the day in question, in which
case the current market price shall be determined in good faith by, and reflected in a formal resolution of, the Board of Directors of the Company. The Company acknowledges and agrees that this Warrant was issued on the Issuance Date. 
  
 3. Transferability and Exchange. 
  
 (a) This Warrant, and the Common Stock issuable upon the exercise hereof,
may not be sold, transferred, pledged or hypothecated unless the Company shall have been provided with an opinion of counsel, or other evidence reasonably satisfactory to it, that such transfer is not in violation of the Securities Act, and any
applicable state securities laws. Subject to the satisfaction of the aforesaid condition, this Warrant and the underlying shares of Common Stock shall be transferable from time to time by the Holder upon written notice to the Company. If this
Warrant is transferred, in whole or in part, the Company shall, upon surrender of this Warrant to the Company, deliver to each transferee a Warrant evidencing the rights of such transferee to purchase the number of shares of Common Stock that such
transferee is entitled to purchase pursuant to such transfer. The Company may place a legend similar to the legend at the top of this Warrant on any replacement Warrant and on each certificate representing shares issuable upon exercise of this
Warrant or any replacement Warrants. Only a registered Holder may enforce the provisions of this Warrant against the Company. A transferee of the original registered Holder becomes a registered Holder only upon delivery to the Company of the
original Warrant and an original Assignment, substantially in the form set forth in Exhibit B attached hereto. 
  
 (b) This Warrant is exchangeable upon its surrender by the Holder to the Company for new Warrants of like tenor and date representing in the aggregate the
right to purchase the number of shares purchasable hereunder, each of such new Warrants to represent the right to purchase such number of shares as may be designated by the Holder at the time of such surrender. 
  
 4. Adjustments to Warrant Price and Number of Shares Subject to
Warrant. The Warrant Price and the number of shares of Common Stock purchasable upon the exercise of this Warrant are subject to adjustment from time to time upon the occurrence of any of the events specified in this Section 4. For the purpose
of this Section 4, “Common Stock” means shares now or hereafter authorized of any class of common stock of the Company and any other stock of the Company, however designated, that has the right to participate in any distribution of
the assets or earnings of the Company without limit as to per share amount (excluding, and subject to any prior rights of, any class or series of preferred stock). 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 (a) In case the Company shall (i) pay a dividend or make a distribution in shares of Common Stock or
other securities, (ii) subdivide its outstanding shares of Common Stock into a greater number of shares, (iii) combine its outstanding shares of Common Stock into a smaller number of shares, or (iv) issue by reclassification of its shares of Common
Stock other securities of the Company, then the Warrant Price in effect at the time of the record date for such dividend or on the effective date of such subdivision, combination or reclassification, and/or the number and kind of securities issuable
on such date, shall be proportionately adjusted so that the Holder of any Warrant thereafter exercised shall be entitled to receive the aggregate number and kind of shares of Common Stock (or such other securities other than Common Stock) of the
Company, at the same aggregate Warrant Price, that, if such Warrant had been exercised immediately prior to such date, the Holder would have owned upon such exercise and been entitled to receive by virtue of such dividend, distribution, subdivision,
combination or reclassification. Such adjustment shall be made successively whenever any event listed above shall occur. 
  
 (b) In case the Company shall fix a record date for the making of a distribution to all holders of Common Stock (including any such distribution made in
connection with a consolidation or merger in which the Company is the surviving corporation) of cash, evidences of indebtedness or assets, or subscription rights or warrants, the Warrant Price to be in effect after such record date shall be
determined by multiplying the Warrant Price in effect immediately prior to such record date by a fraction, the numerator of which shall be the current market price per share of Common Stock on such record date, less the amount of cash so to be
distributed (or the fair market value (as determined in good faith by, and reflected in a formal resolution of, the Board of Directors of the Company) of the portion of the assets or evidences of indebtedness so to be distributed, or of such
subscription rights or warrants, applicable to one share of Common Stock, and the denominator of which shall be such current market price per share of Common Stock. Such adjustment shall be made successively whenever such a record date is fixed; and
in the event that such distribution is not so made, the Warrant Price shall again be adjusted to be the Warrant Price which would then be in effect if such record date had not been fixed. 
  
 (c) For the purpose of any computation under any subsection of this Section 4, the “current market price”
per share of Common Stock on any date shall be the per share price of the Common Stock on the trading day immediately prior to the event requiring an adjustment hereunder and shall be: (i) if the principal trading market for such securities is a
national or regional securities exchange, the closing price on such exchange on such day; or (ii) if sales prices for shares of Common Stock are reported by the Nasdaq National Market System or Small Cap Market System (or a similar system then in
use), the last reported sales price so reported on such day; or (iii) if neither (i) nor (ii) above are applicable, and if bid and ask prices for shares of Common Stock are reported in the over-the-counter market by Nasdaq (or, if not so reported,
by the National Quotation Bureau), the average of the high bid and low ask prices so reported on such day. Notwithstanding the foregoing, if there is no reported closing 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 price, last reported sales price, or bid and ask prices, as the case may be, for the day in question, then the current
market price shall be determined as of the latest date prior to such day for which such closing price, last reported sales price, or bid and ask prices, as the case may be, are available, unless such securities have not been traded on an exchange or
in the over-the-counter market for 30 or more days immediately prior to the day in question, in which case the current market price shall be determined in good faith by, and reflected in a formal resolution of, the Board of Directors of the Company.

  
 (d) Notwithstanding any provision herein to the contrary, no
adjustment in the Warrant Price shall be required unless such adjustment would require an increase or decrease of at least one (1%) percent in the Warrant Price; provided, however, that any adjustments which by reason of this subsection (d) are not
required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this Section 4 shall be made to the nearest cent or the nearest one-hundredth of a share, as the case may be. 
  
 (e) In the event that at any time, as a result of an adjustment made pursuant
to subsection (a) above, the Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon
exercise of any Warrant shall be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the shares of Common Stock contained in this Section 4, and the other provisions
of this Warrant shall apply on like terms to any such other shares. 
  
 (f) If the Company merges or consolidates into or with another corporation or entity, or if another corporation or entity merges into or with the Company (excluding such a merger in which the Company is the surviving or continuing
corporation and which does not result in any reclassification, conversion, exchange, or cancellation of the outstanding shares of Common Stock), or if all or substantially all of the assets or business of the Company are sold or transferred to
another corporation, entity, or person, then, as a condition to such consolidation, merger, or sale (a “Transaction”), lawful and adequate provision shall be made whereby the Holder shall have the right from and after the
Transaction to receive, upon exercise of this Warrant and upon the terms and conditions specified herein and in lieu of the shares of the Common Stock that would have been issuable if this Warrant had been exercised immediately before the
Transaction, such shares of stock, securities, or assets as the Holder would have owned immediately after the Transaction if the Holder had exercised this Warrant immediately before the effective date of the Transaction. 
  
 5. Registration Rights. The Holder shall be entitled to the benefits
of the registration rights set forth in Exhibit C attached hereto. 
  
 6. Reservation of Shares. The Company agrees at all times to reserve and hold available out of its authorized but unissued shares of Common Stock the number of shares of Common Stock issuable upon the full
exercise of this Warrant. The Company further covenants and agrees that all shares of Common Stock that may be delivered upon the exercise of this Warrant will, upon delivery, be fully paid and nonassessable and free from all taxes, liens and
charges with respect to the purchase thereof hereunder. 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 7. Notices to Holder. Upon any adjustment of the Warrant Price (or number of shares of Common
Stock purchasable upon the exercise of this Warrant) pursuant to Section 4, the Company shall promptly thereafter cause to be given to the Holder written notice of such adjustment. Such notice shall include the Warrant Price (and/or the number of
shares of Common Stock purchasable upon the exercise of this Warrant) after such adjustment, and shall set forth in reasonable detail the Company’s method of calculation and the facts upon which such calculations were based. Where appropriate,
such notice shall be given in advance and included as a part of any notice required to be given under the other provisions of this Section 7. 
  
 In the event of (a) any fixing by the Company of a record date with respect to the holders of any class of securities of the Company for the purpose of
determining which of such holders are entitled to dividends or other distributions, or any rights to subscribe for, purchase or otherwise acquire any shares of capital stock of any class or any other securities or property, or to receive any other
right, (b) any capital reorganization of the Company, or reclassification or recapitalization of the capital stock of the Company or any transfer of all or substantially all of the assets or business of the Company to, or consolidation or merger of
the Company with or into, any other entity or person, or (c) any voluntary or involuntary dissolution or winding up of the Company, then and in each such event the Company will give the Holder a written notice specifying, as the case may be (i) the
record date for the purpose of such dividend, distribution, or right, and stating the amount and character of such dividend, distribution, or right; or (ii) the date on which any such reorganization, reclassification, recapitalization, transfer,
consolidation, merger, conveyance, dissolution, liquidation, or winding up is to take place and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such capital stock or securities receivable upon the exercise of
this Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock securities) for securities or other property deliverable upon such event. Any such notice shall be given at least 10 days prior to the earliest date
therein specified. 
  
 8. No Rights as a Stockholder. This
Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company, nor to any other rights whatsoever except the rights herein set forth. 
  
 9. Additional Covenants of the Company. For so long as the Common Stock is listed for trading on any regional or
national securities exchange or Nasdaq (National Market or Small Cap System), the Company shall, upon issuance of any shares for which this Warrant is exercisable, at its expense, promptly obtain and maintain the listing of such shares. The Company
shall comply with the reporting requirements of Sections 13 and 15(d) of the Exchange Act for so long as and to the extent that such requirements apply to the Company. 
  
 The Company shall not, by amendment of its Articles of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 terms of this Warrant. Without limiting the generality of the foregoing, the Company (a) will at all times reserve and
keep available, solely for issuance and delivery upon exercise of this Warrant, shares of Common Stock issuable from time to time upon exercise of this Warrant, (b) will not increase the par value of any shares of capital stock receivable upon
exercise of this Warrant above the amount payable therefore upon such exercise, and (c) will take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable stock.

  
 10. Successors and Assigns. This Agreement shall be
binding upon and inure to the benefit of the Company, the Holder and their respective successors and permitted assigns. 
  
 11. Notices. The Company agrees to maintain a ledger of the ownership of this Warrant (the “Ledger”). Any notice hereunder shall
be given by registered or certified mail if to the Company, at its principal executive office and, if to the Holder, to its address shown in the Ledger of the Company; provided, however, that the Holder may at any time on three (3) days written
notice to the Company designate or substitute another address where notice is to be given. Notice shall be deemed given and received after a certified or registered letter, properly addressed with postage prepaid, is deposited in the U.S. mail.

  
 12. Severability. Every provision of this Warrant is
intended to be severable. If any term or provision hereof is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the remainder of this Warrant. 
  
 13. Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of
Delaware without regard to the conflicts of law thereof. 
  
 14.
Attorneys’ Fees. In any action or proceeding brought to enforce any provision of this Warrant, the prevailing party shall be entitled to recover reasonable attorneys’ fees in addition to its costs and expenses and any other
available remedy. 
  
 15. Entire Agreement. This Warrant
(including the Exhibits attached hereto) constitutes the entire understanding between the Company and the Holder with respect to the subject matter hereof, and supersedes all prior negotiations, discussions, agreements and understandings relating to
such subject matter. 
  
 [Remainder of page intentionally left
blank] 
  

 Placement Agency Agreement paradigm genetics Final Execution 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized
officer as of the date first set forth above. 
  

			
	PARADIGM GENETICS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  

 Placement Agency Agreement paradigm genetics Final Execution 

 Exhibit A 
  
 SUBSCRIPTION FORM 
  
 (To be Executed by the Holder to Exercise the Rights To Purchase Common Stock Evidenced by the Within Warrant) 
  
 The undersigned hereby irrevocably subscribes for
             shares (the “Stock”) of the Common Stock of Paradigm Genetics, Inc. (the “Company”) pursuant to and in accordance with the terms and
conditions of the attached Warrant (the “Warrant”), and hereby makes payment of $             therefore by [tendering cash, wire transferring or delivering a
certified check or bank cashier’s check, payable to the order of the Company] [surrendering              shares of Common Stock received upon exercise of the Warrant, which
shares have a current market price equal to such payment as required in Section 2 of the Warrant]. The undersigned requests that a certificate for the Stock be issued in the name of the undersigned and be delivered to the undersigned at the address
stated below. If the Stock is not all of the shares purchasable pursuant to the Warrant, the undersigned requests that a new Warrant of like tenor for the balance of the remaining shares purchasable thereunder be delivered to the undersigned at the
address stated below. 
  
 In connection with the issuance of the
Stock, I hereby represent to the Company that I am acquiring the Stock for my own account for investment and not with a view to, or for resale in connection with, a distribution of the shares within the meaning of the Securities Act of 1933, as
amended (the “Securities Act”). 
  
 I understand
that because the Stock has not been registered under the Securities Act, I must hold such Stock indefinitely unless the Stock is subsequently registered and qualified under the Securities Act or is exempt from such registration and qualification. I
shall make no transfer or disposition of the Stock unless (a) such transfer or disposition can be made without registration under the Securities Act by reason of a specific exemption from such registration and such qualification, or (b) a
registration statement has been filed pursuant to the Securities Act and has been declared effective with respect to such disposition. I agree that each certificate representing the Stock delivered to me shall bear substantially the same as set
forth on the front page of the Warrant. 
  
 I agree that each
certificate representing the Stock delivered to me shall bear substantially the same legend as set forth on the front page of the Warrant. 
  
 I further agree that the Company may place stop orders on the certificates evidencing the Stock with the transfer agent, if any, to the same effect as the
above legend. The legend and stop transfer notice referred to above shall be removed only upon my furnishing to the Company of an opinion of counsel (reasonably satisfactory to the Company) to the effect that such legend may be removed. 

 

									
	 Dated:
	 	  

	 	 	 	Signed:	 	  

	 	 	 	 	 	 	Address:	 	  

					
	 	 	 	 	 	 	 	 	

  

 Placement Agency Agreement paradigm genetics Final Execution 

 Exhibit B 
  
 ASSIGNMENT 
  
 (To be Executed by the Holder to Effect Transfer of the Attached Warrant) 
  
 FOR VALUE RECEIVED
                                        
                     hereby sells, assigns and transfers to
                                        
the Warrant attached hereto and the rights represented thereby to purchase              shares of Common Stock in accordance with the terms and conditions hereof, and does hereby
irrevocably constitute and appoint
                                        
                 as attorney to transfer such Warrant on the books of the Company with full power of substitution. 
  

									
	 Dated:
	 	  

	 	 	 	Signed:	 	  

  

			
	 Please print or type name
 and address of
Assignee:
	 	 Please insert Social Security or
 Tax Identification
Number of Assignee:

	  
  

	 	  
  

	  

	 	 
	  

	 	 

  

 Placement Agency Agreement paradigm genetics Final Execution

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]